MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Quarterly Earnings Results, Misses Expectations By $0.16 EPS

MoonLake Immunotherapeutics (NASDAQ:MLTX) issued its quarterly earnings results on Wednesday. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.16), FiscalAI reports.

MoonLake Immunotherapeutics Stock Down 1.2%

Shares of NASDAQ MLTX traded down $0.14 during mid-day trading on Wednesday, reaching $11.56. The company had a trading volume of 956,691 shares, compared to its average volume of 1,534,635. The company has a debt-to-equity ratio of 0.23, a quick ratio of 12.56 and a current ratio of 12.56. MoonLake Immunotherapeutics has a twelve month low of $9.46 and a twelve month high of $23.29. The stock’s 50 day moving average is $12.36 and its 200-day moving average is $16.41. The stock has a market capitalization of $983.79 million, a PE ratio of -3.01 and a beta of 1.14.

Analyst Ratings Changes

MLTX has been the subject of a number of research reports. Wall Street Zen lowered MoonLake Immunotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, September 27th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of MoonLake Immunotherapeutics in a report on Monday, October 5th. Weiss Ratings raised shares of MoonLake Immunotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of MoonLake Immunotherapeutics in a report on Wednesday, September 16th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, MoonLake Immunotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $28.50.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases. The company is advancing medicines designed to address conditions in which the immune system contributes to chronic inflammation and tissue damage.

Its lead product candidate is sonelokimab, an investigational Nanobody-based therapy designed to selectively inhibit interleukin-17A and interleukin-17F, two cytokines involved in inflammatory disease.